Abstract: Provided herein are compositions of NK-92™ cells that express a combination of PD-L1 CAR, CD16 and IL2, and the method of using these cells to reduce tumor cells and cells in tumor microenvironment (e.g., MDSCs or TAMs) and treat cancer.
Type:
Grant
Filed:
August 1, 2019
Date of Patent:
August 3, 2021
Assignee:
NantKwest Inc.
Inventors:
Hans G. Klingemann, Laurent H. Boissel, Abhijit Dandapat
Abstract: Provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) a homing receptor, ii) Antigen Binding Protein (ABP) or Chimeric Antigen Receptor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Further provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) IL-12 and/or TGF-beta trap, ii) an Antigen Binding Protein (ABP) or Chimeric Antigen Receptor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Also provided are compositions and kits comprising the modified NK-92® cells, as well as methods of treating cancer using the modified cells.
Type:
Grant
Filed:
December 9, 2019
Date of Patent:
July 13, 2021
Assignee:
NantKwest, Inc.
Inventors:
Hans G. Klingemann, Laurent H. Boissel, Nathan T. Schomer
Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.
Type:
Grant
Filed:
June 17, 2020
Date of Patent:
May 11, 2021
Assignee:
NANTKWEST, INC.
Inventors:
Tien Lee, Hans G. Klingemann, Barry J. Simon, Laurent Boissel
Abstract: Provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) a homing receptor, ii) Antigen Binding Protein (ABP) or Chimeric Antigen Recpetor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Further provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) IL-12 and/or TGF-beta trap, ii) an Antigen Binding Protein (ABP) or Chimeric Antigen Recpetor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Also provided are compositions and kits comprising the modified NK-92® cells, as well as methods of treating cancer using the modified cells.
Type:
Grant
Filed:
August 1, 2019
Date of Patent:
March 30, 2021
Assignee:
NantKwest, Inc.
Inventors:
Hans G. Klingemann, Laurent H. Boissel, John H. Lee, Nathan T. Schomer
Abstract: Provided herein are populations of modified NK-92 cells, compositions and kits comprising the cells, and methods of making and using the populations of cells.
Type:
Grant
Filed:
March 7, 2018
Date of Patent:
October 13, 2020
Assignee:
NantKwest, Inc.
Inventors:
Hans Klingemann, Laurent Boissel, Patrick Soon-Shiong
Abstract: Described herein are methods for treating or preventing leukemias with NK-92 cells. In particular, provided are methods of treating or preventing leukemias by administering to a patient one or more doses of NK-92 cells for killing remnant (also referred to as residual) leukemia cells and/or leukemia stem cells. In various embodiments, NK-92 cells are administered to a patient to treat and/or prevent leukemia that is refractory or resistant, or has relapsed in a patient who is recovering from treatment for leukemia under conventional therapies.
Abstract: Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.
Abstract: Provided herein are populations of modified NK-92 cells, compositions and kits comprising the cells, and methods of making and using the populations of cells.
Type:
Grant
Filed:
May 28, 2019
Date of Patent:
September 15, 2020
Assignee:
NantKwest, Inc.
Inventors:
Hans Klingemann, Laurent Boissel, Patrick Soon-Shiong
Abstract: Provided herein are compositions of NK-92® cells that express a CD19 CAR, CD16 and IL2, and the method of using these cells to and treat cancer in a patient.
Type:
Grant
Filed:
August 1, 2019
Date of Patent:
September 8, 2020
Assignee:
NantKwest, Inc.
Inventors:
Hans G. Klingemann, Laurent H. Boissel, Patrick Soon-Shiong
Abstract: Provided herein are NK-92 cells expressing at least one CAR and at least one Fc receptor. Also provided are methods of treatment of a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer, comprising administering to the patient NK-92-Fc-CAR.
Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.
Type:
Grant
Filed:
August 15, 2019
Date of Patent:
August 11, 2020
Assignee:
NantKwest, Inc.
Inventors:
Tien Lee, Hans G. Klingemann, Barry J. Simon, Laurent Boissel
Abstract: Provided herein are methods of treating merkel cell carcinoma. The methods include selecting a subject having merkel cell carcinoma and administering to the subject a therapeutically effective amount of NK-92 cells, wherein administration treats the merkel cell carcinoma in the subject.
Type:
Application
Filed:
June 19, 2018
Publication date:
June 4, 2020
Applicant:
NANTKWEST, INC.
Inventors:
Hans Klingemann, Tien Lee, Laurent Boissel
Abstract: Chordoma is treated in a patient by co-administration of an anti-EGFR antibody and high affinity NK cells (haNK). Most preferably, the antibody is non-covalently bound to a high affinity variant of a CD16 receptor or administered before transfusion of the haNK cells to so target the chordoma cells for cytotoxic cell killing by the haNK cells.
Abstract: Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.
Abstract: Provided herein are methods of treating merkel cell carcinoma. The methods include selecting a subject having merkel cell carcinoma and administering to the subject a therapeutically effective amount of NK-92 cells and a therapeutically effective amount of an IL-15 agonist, wherein administration treats the merkel cell carcinoma in the subject.
Type:
Application
Filed:
June 19, 2018
Publication date:
April 23, 2020
Applicant:
NANTKWEST, INC.
Inventors:
Hans Klingemann, Tien Lee, Laurent Boissel
Abstract: Provided are CD96-modified and TIGIT-modified NK-92 cells comprising one or more alterations that inhibit expression of CD96 and/or TIGIT. Also provided are methods of generating such modified NK-92 cells and methods of treating a subject having or suspected of having a cancer using the modified NK-92 cells.
Abstract: Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.
Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.
Type:
Grant
Filed:
March 25, 2016
Date of Patent:
October 29, 2019
Assignee:
NantKwest, Inc.
Inventors:
Tien Lee, Hans G. Klingemann, Barry J. Simon, Laurent Boissel
Abstract: Provided herein are populations of modified NK-92 cells, compositions and kits comprising the cells, and methods of making and using the populations of cells.
Type:
Application
Filed:
May 28, 2019
Publication date:
October 3, 2019
Applicant:
NantKwest, Inc.
Inventors:
Hans Klingemann, Laurent Boissel, Patrick Soon-Shiong
Abstract: Described herein are modified NK-92 cells comprising a genetic alteration to decrease beta-2-microglobulin (B2M) expression in NK-92 cells to reduce the levels of HLA class I expression; methods of generating such cells; and methods of treating a subject, e.g., that has cancer, with the B2M-modified NK-92 cells.